基于ATP-TCA在消化道肿瘤中的临床应用研究  

Clinical Application of ATP-TCA in Digestive Tract Tumors

作　　者：赖家骏[1] 李康 何盛泉[1] 张涛[1] Lai Jiajun(Department of Gastrointestinal surgery,North Guangdong people's Hospital,Shaoguan Guangdong 512025)

机构地区：[1]粤北人民医院胃肠外科

出　　处：《黑龙江医药》2020年第1期18-20,共3页Heilongjiang Medicine journal

基　　金：2016年韶关市卫生计生科研立项(编号:Y16020),项目名称:基于ATP-TCA在消化道肿瘤中的临床应用研究

摘　　要：目的:探讨ATP-TCA在消化道肿瘤中的临床应用价值及效果。方法:取本院确认的消化道肿瘤患者100例,时间段为2016年6月1日至2018年6月30日,根据ATP-TCA药敏结果将其分为化疗药物敏感组(n=50)和耐药组(n=50)。比较两组的近期和远期临床效果。结果:药敏组患者的临床近期疾病总控制率明显高于耐药组(P<0.05),随访1年,药敏组患者的生存率明显高于耐药组(P<0.05)。结论:对于消化道肿瘤患者采用ATP-TCA药敏试验,能明显为患者临床有效治疗提供重要的依据,提高患者临床疗效和生存率,具有积极的推广价值。Objective: To investigate the clinical application value and effect of ATP-TCA in digestive tract tumors. Methods: 100 cases of patients with digestive tract tumors confirmed by our hospital were selected,and the time period was June 1,2016,solstice,June 30,2018. According to the drug sensitivity results of ATP-TCA,they were divided into the chemotherapy-sensitive group( n =50) and the drug resistance group( n = 50). The short-term and long-term clinical effects of the two groups were compared. Results:The overall control rate of clinical recent diseases of patients in the drug sensitive group was significantly higher than that in the drug resistant group( P<0.05). The survival rate of patients in the drug sensitive group was significantly higher than that in the drug resistant group( P<0.05). Conclusion: ATP-TCA drug sensitivity test for patients with digestive tract tumors can obviously provide important basis for effective clinical treatment of patients,improve the clinical efficacy and survival rate of patients,and has positive promotion value.

关 键 词：消化道肿瘤 ATP-TCA 药敏测试 临床价值 

分 类 号：R735[医药卫生—肿瘤]